Thymulin Analog (PAT)
Synthetic thymulin-derived nonapeptide with potent analgesic and anti-inflammatory properties
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Typical dose
1 mcg–50 mcg mcg
Compound profile
Scientific & efficacy data
Healing & Recovery
Peptide profile
Strong human trials
Thymulin Analog (PAT)
1 mcg–50 mcg mcg · Once daily
Molecular formula
C37H62N12O15
- Mol. weight
- 858.9 Da
- CAS number
- Not assigned
- PubChem
- Not available
- Developed · 2006
- Multiple independent researchers (polypharmacy peptide)
Various research institutions and cosmetic companies
Amino acid sequence
pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn (nonapeptide)Pain Relief
Demonstrates analgesic potency comparable to or exceeding morphine and NSAIDs in multiple preclinical pain models including CCI and SNI neuropathy
Anti-Inflammatory
Potent inhibitor of NF-κB signaling and pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, NGF) through alpha-7 nicotinic receptor potentiation
Neuroprotection
Reduces cerebral neuroinflammation and cytokine upregulation following immune challenge, suggesting potential neuroprotective applications
Dosing
How much do I take?
Covers timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for neuropathic pain research & anti-inflammatory therapy development
Best for
Neuropathic pain research
Thymulin Analog (PAT) is particularly well-suited for individuals focused on neuropathic pain research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-inflammatory therapy development
Thymulin Analog (PAT) is particularly well-suited for individuals focused on anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Novel analgesic mechanism investigation
Thymulin Analog (PAT) is particularly well-suited for individuals focused on novel analgesic mechanism investigation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cytokine-mediated pain pathway studies
Thymulin Analog (PAT) is particularly well-suited for individuals focused on cytokine-mediated pain pathway studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Thymulin Analog (PAT) with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Intraperitoneal injection · Intracerebroventricular injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 2 serious
Thymulin Analog (PAT) is a synthetic 9-amino acid peptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is a research compound ONLY—NOT approved for human use.
No serious adverse effects have been documented in extensive preclinical studies spanning 17+ years. However, this is a critical limitation: all data comes from animal models (primarily rats and mice). Zero completed human clinical trials exist.
The peptide has not undergone human Phase 1 safety testing. No manufactured batches meet pharmaceutical standards. PAT's primary mechanism—alpha-7 nAChR potentiation—could theoretically affect multiple organ systems, but human safety data is absent.
As an immune-modulating compound, prolonged high-dose use could theoretically suppress protective immunity, though animal studies show no adverse effects at therapeutic doses. Individual responses in humans are completely unknown.
Thymulin Analog (PAT) evidence comes entirely from preclinical animal studies published in peer-reviewed journals over 17+ years of investigation. No Phase 1 human clinical trials have been completed.
All safety and efficacy data is extrapolated from rodent models studying immune modulation via alpha-7 nicotinic acetylcholine receptor activity.
Common side effects · experienced by some users
Injection Site Reaction
Theoretical local reaction at intraperitoneal injection site; not specifically documented as adverse in published studies
Management: Rotate injection sites; standard aseptic technique
Transient Immune Modulation
As an immune-modulating peptide, PAT may transiently alter cytokine profiles beyond the target inflammatory site
Management: Monitor cytokine levels in research settings; effects expected to be reversible upon discontinuation
Mild Sedation
Theoretical central nervous system effect at high doses given cholinergic pathway involvement; not observed at standard research doses
Management: Dose adjustment if behavioral changes noted in animal models
Short Duration of Action
Single-dose effects diminish by 3-4 hours post-administration, requiring repeated dosing for sustained relief
Management: Daily dosing protocols show progressive improvement; extended-release formulations not yet developed
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Thymulin Analog (PAT)
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Thymulin Analog (PAT) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Alpha-7 nAChR Research Tools — Combining with receptor-specific agonists and antagonists elucidates PAT mechanism of action through cholinergic pathways
- Safe:Cytokine Assays — Monitoring IL-1β, IL-6, TNF-α, and NGF levels validates anti-inflammatory efficacy in research models
- Safe:Neuropathic Pain Models — CCI and SNI models provide validated platforms for assessing PAT analgesic potency
With medications
- Caution:Strong Immunosuppressants — May compound immune suppression through overlapping anti-inflammatory mechanisms
- Caution:Nicotinic Receptor Antagonists — Alpha-7 nAChR antagonists like methyllycaconitine block PAT primary mechanism of action
- Caution:High-Dose Corticosteroids — Redundant anti-inflammatory pathways may confound research outcomes or cause excessive immune suppression
With supplements
- Safe:Multivitamins — Generally safe to take alongside Thymulin Analog (PAT). Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Strong human trials · first signs acute effects (1-4 hours)
Evidence level
Strong human trials
(Phase 3 or FDA approved)
Regulatory status
Research compound
Onset of effects
Moderate
(1-2 weeks)
How it works
Thymulin analog is a synthetic peptide that mimics the immune-regulating thymus hormone, helping balance immune function and reduce inflammation.
It enhances immune cell maturation and supports your body's natural healing responses, making it useful for skin health and recovery from damage.
The deeper mechanism
Thymulin (also called thymic factor or facteur thymique sérique - FTS) is a 9-amino acid peptide hormone produced by thymic epithelial cells that regulates T-cell maturation and differentiation.
Synthetic thymulin analogs mimic the endogenous peptide's structure and biological activity, promoting Th1/Th2 balance, enhancing CD4+ T cell differentiation, and supporting thymic function.
Thymulin analogs activate thymulin receptors on immature thymocytes and peripheral T cells, promoting IL-2 production and T cell receptor (TCR) expression required for proper immune maturation.
In skin, thymulin supports skin-associated lymphoid tissue (SALT) function, enhances antigen presentation capacity, and promotes wound healing through IL-10 and TGF-β production. Topical thymulin improves skin immune surveillance and supports barrier repair.
What to expect
Acute Effects (1-4 Hours)
What you might notice
- Peak analgesic and anti-inflammatory effects at 1-2 hours post-injection;
- significant reduction in mechanical allodynia and thermal hyperalgesia
What's normal
- Initial response to Thymulin Analog (PAT) is beginning at the cellular level
- Different individuals experience Thymulin Analog (PAT)'s onset at different rates
- Transient systemic effects from initial Thymulin Analog (PAT) exposure are common
What's next
- Maintain consistent Thymulin Analog (PAT) administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Repeated Dosing (Days to Weeks)
What you might notice
- Progressive improvement in pain outcomes with daily administration;
- cumulative anti-inflammatory effects observed in neuropathic pain models
What's normal
- Thymulin Analog (PAT) is achieving sufficient receptor engagement
- Initial mechanism of Thymulin Analog (PAT) is taking effect
- Early transient effects from Thymulin Analog (PAT) administration are resolving
What's next
- Maintain consistent Thymulin Analog (PAT) administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Research Endpoint (2-4 Weeks)
What you might notice
- Maximum therapeutic effects achieved in chronic neuropathic pain models;
- sustained cytokine suppression and neuroinflammation reduction
What's normal
- Full therapeutic effects of Thymulin Analog (PAT) are well-characterized at this point
- Maintenance of Thymulin Analog (PAT)'s therapeutic effects is typical
- Tolerance patterns with Thymulin Analog (PAT) are generally stable over months
What's next
- Comprehensive assessment of Thymulin Analog (PAT) efficacy should be conducted
- Discuss long-term continuation, cycling, or protocol modifications
- Continue regular monitoring of relevant biomarkers or symptoms
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Thymulin Analog (PAT) over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked
How does PAT differ from native thymulin?
While PAT shares the same 9-amino acid sequence as native thymulin (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn), it was specifically designed to eliminate the biphasic response of native thymulin, which produces hyperalgesia at low doses through PGE2-dependent mechanisms. PAT retains only the analgesic and anti-inflammatory properties, providing superior therapeutic effects at lower concentrations.
Is PAT available for clinical use?
No, PAT is currently a research compound that has not entered human clinical trials. All available data comes from extensive preclinical animal studies spanning over 17 years. The peptide is protected under US Patent 7,309,690 B2 for pain treatment applications, but clinical translation has not yet occurred.
What pain conditions has PAT been tested against?
PAT has demonstrated efficacy in multiple preclinical pain models including chronic constriction injury (CCI) neuropathy, spared nerve injury (SNI) mononeuropathy, endotoxin-induced inflammatory hyperalgesia, carrageenan inflammation, and capsaicin-induced hyperalgesia. Effects have been confirmed across mechanical allodynia, thermal hyperalgesia, and various pain assessment tests.
How does PAT compare to existing analgesics?
In direct preclinical comparisons, PAT demonstrated analgesic effects equal to or exceeding morphine and meloxicam at equivalent doses. Unlike opioids, PAT showed no signs of central nervous system depression, and unlike NSAIDs, it achieved anti-inflammatory effects superior to indomethacin and dexamethasone at lower doses without apparent gastrointestinal or renal toxicity.
What is PAT's primary mechanism of action?
PAT primarily acts through potentiation of alpha-7 nicotinic acetylcholine receptors (α7-nAChR), which activates the cholinergic anti-inflammatory pathway. This was confirmed through electrophysiological studies in Xenopus oocyte expression systems and behavioral pharmacology showing that alpha-7 antagonists reverse PAT effects. This mechanism leads to downstream NF-κB inhibition and cytokine suppression.
What are the prospects for PAT entering clinical trials?
While PAT has a strong preclinical evidence base with over 15 peer-reviewed publications and consistent results across multiple pain models, several gaps remain before clinical translation. These include comprehensive pharmacokinetic profiling, formal toxicology studies, determination of optimal human dosing and administration routes, and regulatory requirements for an Investigational New Drug (IND) application.
Further reading
History & related research
History · since 1979
A modified hormone that fights inflammation and pain without needing a rare mineral.
Thymulin is a natural hormone your thymus gland makes. The thymus is a small gland behind your breastbone that helps your immune system grow strong.
Read the full history of Thymulin Analog (PAT)Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Thymulin Analog (PAT), on one page.